Australia has potential to reduce lung cancer deaths, major international clinical trials show

lungs
Credit: Pixabay/CC0 Public Domain

A new study by the Daffodil Center, published in the British Journal of Cancer, has strengthened the economic case for a targeted lung cancer screening program in Australia.

The study updates cost-effectiveness estimates in an Australian context based on the findings of two major international trials of , the Dutch-Belgian NELSON trial and the U.S. National Lung Screening Trial.

A/Professor Marianne Weber, leader of the Daffodil Center's Lung Cancer stream, said the study showed that if trial results were adapted into the Australian health system, lung cancer screening for Australians with a history of heavy smoking would have a favorable cost-effectiveness ratio given new evidence from the NELSON trial published in 2020.

She said the results helped inform the recommendation to government from the independent Medical Services Advisory Committee (MSAC) supporting the implementation of a targeted national lung cancer screening program, announced earlier this month.

"The greatest challenge in cancer screening is ensuring that it delivers more benefit than harm to the population," A/Professor Weber said. "For most cancers, there are no tests for asymptomatic populations that work without causing significant harms, such as inaccurate results that lead to unnecessary harmful diagnostic tests and treatments, stress for individuals affected and out-of-pocket costs.

"Governments also consider cost-effectiveness as a matter of course. These results, which show targeted lung cancer screening using low-dose computed tomography could be more cost-effective than previous estimates indicated, strengthen the economic case for a targeted lung cancer screening program."

Professor Karen Canfell, director of the Daffodil Center, Chair of Cancer Council's Cancer Screening and Immunization Committee, and senior author on the study, said Australia was a world leader in cancer screening, yet opportunities for optimal screening outcomes were not always realized.

"Australia is on track to be the first country to eliminate through a combination of immunization, screening and treatment, and our bowel and breast cancer screening programs are among the world's best," Professor Canfell said.

"The overseas NELSON trial (Dutch-Belgian) and National Lung Screening Trial (U.S.) both showed lives could be saved. However, translating those results will require a focus on optimal implementation to ensure a new lung screening program reaches those who will benefit and that it operates effectively within Australia's unique health system.

"The key will be for government to continue to work with independent researchers and other stakeholders in considering optimal policy and practice for the early detection of lung cancer, Australia's leading cause of cancer death."

Australia has the potential to reduce lung cancer deaths by up to 24% by applying screening parameters and outcomes from international trials.

"We support continued investment in work to enhance the and success of a targeted lung cancer screening program in Australia. It's now time for the Federal Government to act on the evidence and implement a targeted program to detect more cancers earlier," Professor Canfell concluded.

This paper is only one component of a broader program of work at the Daffodil Center which aims to reduce the impact of lung in Australia.

More information: Silvia Behar Harpaz et al, Updated cost-effectiveness analysis of lung cancer screening for Australia, capturing differences in the health economic impact of NELSON and NLST outcomes, British Journal of Cancer (2022). DOI: 10.1038/s41416-022-02026-8

Journal information: British Journal of Cancer

Provided by Cancer Council
Citation: Australia has potential to reduce lung cancer deaths, major international clinical trials show (2022, November 8) retrieved 8 February 2023 from https://medicalxpress.com/news/2022-11-australia-potential-lung-cancer-deaths.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Consumer health: What is lung cancer screening, and who needs it?

15 shares

Feedback to editors